UAE Becomes World’s Third Country to Approve MIEBO for Dry Eye Treatment
The United Arab Emirates has become the third country in the world to approve MIEBO, an innovative prescription treatment designed for patients suffering from dry eye disease. The approval was granted by the Emirates Drug Establishment (EDE), marking another major milestone in the UAE’s growing reputation as a global leader in advanced healthcare and pharmaceutical innovation.
Developed by Bausch + Lomb, MIEBO contains the active ingredient perfluorohexyloctane and is considered the first prescription eye drop specifically designed to target tear evaporation — one of the primary causes of dry eye disease.
What Is Dry Eye Disease?
Dry eye disease is a common eye condition that occurs when the eyes do not produce enough tears or when tears evaporate too quickly. This condition can lead to symptoms such as:
- Eye irritation
- Burning sensation
- Redness
- Blurred vision
- Sensitivity to light
- Eye fatigue
The condition has become increasingly common due to prolonged screen time, heavy digital device usage, air-conditioned environments, pollution, and climate-related factors. Millions of people worldwide are affected by dry eye syndrome, impacting their comfort, productivity, and overall quality of life.
How MIEBO Works
Unlike traditional artificial tears that mainly provide temporary lubrication, MIEBO directly targets excessive tear evaporation by forming a protective layer over the eye surface. This helps stabilize the tear film and provides longer-lasting relief from dry eye symptoms.
The treatment is considered a breakthrough because it addresses the root cause of evaporative dry eye rather than simply masking symptoms.
According to healthcare experts, the medication may significantly improve comfort for patients who spend long hours using computers, smartphones, and digital devices — a growing issue in modern lifestyles.
UAE Strengthens Position in Healthcare Innovation
With this approval, the UAE joins a very small group of countries offering patients early access to cutting-edge ophthalmology treatments. The decision reflects the country’s strategy to accelerate access to advanced medicines and strengthen the pharmaceutical ecosystem according to international healthcare standards.
The UAE has increasingly positioned itself as a regional hub for medical innovation, advanced therapies, and rapid drug approvals. Health authorities continue to focus on improving patient care through faster adoption of breakthrough treatments across multiple medical fields.
Clinical Studies and Effectiveness
The approval of MIEBO was supported by positive results from two major clinical studies — GOBI and MOJAVE — involving more than 1,200 patients. The studies demonstrated statistically significant improvements in both the signs and symptoms of dry eye disease during treatment.
Experts believe the introduction of MIEBO could benefit a large number of patients who struggle with chronic dry eye symptoms that are not adequately controlled by conventional eye drops.
Rising Need for Advanced Eye Care
The demand for advanced eye treatments is rising globally due to increasing digital screen exposure and changing lifestyles. Research indicates that dry eye disease has become one of the most common eye disorders worldwide.The UAE’s approval of MIEBO highlights the country’s proactive approach to adopting innovative medical technologies and improving healthcare outcomes for residents.As awareness about eye health continues to grow, specialists emphasize the importance of regular eye checkups, reducing excessive screen exposure, staying hydrated, and seeking medical advice for persistent eye discomfort.